Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics announced receipt of a second philanthropic donation that allows the continuation of its expanded access program (EAP) providing Zervimesine (CT1812) treatment to patients with Dementia with Lewy Bodies (DLB). The EAP, launched in 2025 and currently serving 32 participants, is now extended to two years of treatment. Positive …